The table below shows Corvus Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$10.37M
-$8.26M
-$5.16M
-$8.11M
-$6.42M
-$8.79M
Capital expenditure
$91.00K
$36.00K
-
$34.00K
-
-
Investing cash flow
-$144.85M
$4.24M
-$7.00K
$4.60M
-$25.57M
$4.85M
Dividends paid
-
-
-
-
CRVS operating cash flow (10-K history)
Corvus Pharmaceuticals, Inc. reported operating cash flow of -$32.80M for fiscal year 2025. That is down 29.0% from -$25.42M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$27.86M (FY 2016) to -$32.80M. Figures come from the company's audited annual reports as filed with the SEC.